MedTrace Logo

Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals

NCT02621242 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2024-07-12

Study results available
· View outcomes & findings →

Summary

As explained in detail in a recently published hypothesis article (Hladik F. A new hypothesis on HIV cure. F1000Research, 4:77 (2015)), the investigators hypothesize that NRTI drugs may reduce the likelihood of HIV eradication by promoting the survival of cells with integrated provirus. In this study, the investigators will test whether daily oral use of two NTRI drugs, tenofovir and emtricitabine (Truvada Pill), induces changes in the upper and lower gut mucosa that are congruent with supporting this hypothesis.

Conditions

Interventions

PROCEDURE

Upper endoscopy

Upper endoscopy with biopsies

PROCEDURE

Anoscopy

Anoscopy with biopsies

DRUG

Truvada

Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.

Sponsors & Collaborators

Principal Investigators

  • Joanne Stekler, MD · University of Washington

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02621242 on ClinicalTrials.gov